CROSS-FILE REVIEW
Four Peptides. Three Questions. No Shortcuts.
Mechanism, evidence maturity, and regulatory status are separate columns because merging them produces bad conclusions.
In plain English
These compounds should not be ranked on one scale from “good” to “bad.” They answer different research questions and carry radically different evidence. Tesamorelin stimulates the growth-hormone axis and is approved for one narrow HIV-associated condition. Semaglutide acts at the GLP-1 receptor and has large clinical programs. Ipamorelin also influences growth-hormone release, but through the ghrelin receptor; it remains unapproved, and its only controlled efficacy trial missed its main endpoint [15]. BPC-157 is proposed as a repair peptide, yet nearly all supportive work remains in animals or cells [19][21][22].
FDA approval identifies a reviewed product and use. Compounding rules govern limited pharmacy preparation. Published evidence asks whether a claim survived a study. A compound may have a plausible mechanism without a proven benefit, or approval for one indication without evidence for another. The table keeps those distinctions intact.
The evidence ledger
| Compound | Primary mechanism | Best human evidence | FDA status | Principal uncertainty |
|---|---|---|---|---|
| Tesamorelin | GHRH-receptor agonism | Randomized trials and pooled analysis in HIV-associated lipodystrophy [1][3][5][6] | Approved for one narrow indication | Generalization and long-term GH-axis risk |
| Semaglutide | GLP-1 receptor agonism | Large weight, cardiovascular, and kidney trials [9][10][11] | Approved for specific indications | Tolerability and product equivalence outside approved supply |
| Ipamorelin | Ghrelin-receptor agonism | Failed efficacy study; small pharmacology cohorts [15][16] | Not approved | Long-term human safety and efficacy |
| BPC-157 | Proposed angiogenic repair signaling | Tiny pilots; mainly animal and cell work [18][19][21][22] | Not approved | Nearly the entire clinical profile |
The ledger is deliberately unsymmetrical. Evidence quality is not improved by giving every molecule the same number of favorable sentences.
Mechanism is not maturity
Tesamorelin and ipamorelin both converge on growth-hormone release, but engage different receptors. Only tesamorelin has an approved indication and a multi-trial efficacy record [1][3][5][6]. Ipamorelin's selectivity explains experimental appeal, while its outcome record remains inadequate [15][16]. Semaglutide occupies another system. Its GLP-1 pathway influences insulin, glucagon, appetite, and gastric emptying, backed by dedicated outcomes trials [9][10][11]. BPC-157 is farther from clinical maturity. Its VEGFR2 story is largely experimental [21]. Mechanistic evidence can explain a hypothesis; it cannot answer whether a patient benefits overall.
Approval, compounding, and access
FDA approval is the clearest regulatory dividing line, but remains product- and indication-specific. Tesamorelin and semaglutide have approved uses. Ipamorelin and BPC-157 do not. Approval does not authorize broad off-label marketing, and unapproved status is not corrected by changing suppliers or labels.
Compounding is a separate legal pathway with conditions and limitations. It does not reproduce FDA premarket review. Nor does it turn evidence for one formulation into proof about another. During access disruptions, discussion often treats availability as scientific endorsement. It is not. Confirm the exact product, indication, evidence population, and regulatory statement. If those nouns change, the conclusion may change.
What comparisons cannot answer
This page cannot determine which compound fits an individual because the four are not interchangeable treatments. It cannot rank unregulated products by quality; their identity and sterility are outside the cited record. It cannot treat community enthusiasm as a surrogate endpoint. Reports of sleep, recovery, appetite change, or tissue repair remain anecdotal, not clinical evidence unless tested under controlled conditions.
The page answers a narrower question: how far does the record reach? For semaglutide, large human outcomes. For tesamorelin, a narrow approved HIV-associated use. For ipamorelin, short pharmacology and one unsuccessful efficacy trial. For BPC-157, preclinical mechanisms and an exceptionally small human foothold.